The Year of the IPO continues! We wrote about the parallels between Pinterest and early Facebook, we did an extensive Slack S-1 read-through, and we highlighted what Uber and Lyft are saying about autonomous vehicles in their filings.
After Chewy’s first IPO filing in late April (latest S-1/A here), we are looking at what we can learn about pet industry valuations — both from trading data and from what is buried deep in SEC filings — in the form of fairness opinions filed around M&A activity in the sector.
Chewy (CHWY) does not have direct US comparables. There are no other dominant online pet food or pet medicine specialists. There used to be two publicly traded “pure play” pet food companies: Blue Buffalo (old ticker: BUFF) and FreshPet (FRPT). FRPT still trades, while BUFF was taken over by General Mills.
FRPT pioneered fresh, refrigerated pet food that is delivered to stores and sold in branded coolers, in contrast to Chewy’s online model of shelf-stable food combined with a large subscription business. After a rocky post-IPO start, FRPT is in the middle of a successful turnaround, and the company is currently trading at around 6.5x EV/NTM Sales and at around 48x EV/NTM EBITDA. Interactive chart
BUFF, on the other hand, offers traditional, shelf-stable food. BUFF was acquired by General Mills last year, and was trading at 5.7x EV/NTM Sales and 23.1x EV/NTM EBITDA at takeover time. Interactive chart
Since the General Mills-Blue Buffalo transaction was likely cited in fairness opinions, we searched all Consumer Staples company filings for tables that contain “Blue Buffalo.” We found one right away, literally the first result: Pinnacle Foods’ filings around its takeout by ConAgra Brands (CAG) (Full document here). We see that there are three recent pet food transactions that are of relevance to our work on CHWY: BUFF taken out at 25.5x EV/LTM EBITDA, Ainsworth Pet Nutrition at 20.0x, and Big Heart Pet Brands at 15.1x.
Going beyond food, we also took a look at the pet health players. There are three segments that we looked at: pet/animal pharmaceuticals, pet hospitals, and pet health insurance. There are US publicly traded companies in the pharmaceutical and the insurance space.
On the pharma side, we took a look at Idexx Laboratories (IDXX), Zoetis (ZTS), Elanco Animal Health (ELAN), and Phibro Animal Health (PAHC). We can see that the median animal pharma name is trading at 20.4x NTM EV/EBITDA.
Originally Posted on June 7, 2019
DISCLAIMER: Nothing on this website should be considered investment advice. We do not make recommendations (long or short) in any securities. We do not express opinions as to whether any company’s accounting practices are in violation of SEC, GAAP, IFRS or other rules/regulations.
Disclosure: Interactive Brokers
Information posted on IBKR Traders’ Insight that is provided by third-parties and not by Interactive Brokers does NOT constitute a recommendation by Interactive Brokers that you should contract for the services of that third party. Third-party participants who contribute to IBKR Traders’ Insight are independent of Interactive Brokers and Interactive Brokers does not make any representations or warranties concerning the services offered, their past or future performance, or the accuracy of the information provided by the third party. Past performance is no guarantee of future results.
This material is from Sentieo and is being posted with permission from Sentieo. The views expressed in this material are solely those of the author and/or Sentieo and IBKR is not endorsing or recommending any investment or trading discussed in the material. This material is not and should not be construed as an offer to sell or the solicitation of an offer to buy any security. To the extent that this material discusses general market activity, industry or sector trends or other broad based economic or political conditions, it should not be construed as research or investment advice. To the extent that it includes references to specific securities, commodities, currencies, or other instruments, those references do not constitute a recommendation to buy, sell or hold such security. This material does not and is not intended to take into account the particular financial conditions, investment objectives or requirements of individual customers. Before acting on this material, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.